Frontiers in Health Informatics
ISSN-Online: 2676-7104
www.healthinformaticsjournal.com
2024; Vol 13: Issue 2
Open Access

# REVIEW ON UPDATED METHODS OF LC-MS/MS IN CLINICAL DIAGNOSTICS

**Kuturu Deepthi***
Research Scholar, Department of Pharmacy, Mewar University, Chittorgarh-312901, Rajasthan, India.

***Corresponding author: Kuturu Deepthi***
Research Scholar, Department of Pharmacy, Mewar University, Chittorgarh-312901, Rajasthan, India
Email ID- deepurdy.reddy57@gmail.com

Cite this paper as: Kuturu Deepthi (2024) Review On Updated Methods Of Lc-Ms/Ms In Clinical Diagnostics. *Frontiers in Health Informa* 869-889

**Abstract**
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) has become a cornerstone in clinical diagnostics, offering unparalleled sensitivity, specificity, and versatility. This review explores the latest advancements in LC-MS/MS methodologies and their applications in laboratory medicine and patient care. By combining the separation efficiency of liquid chromatography with the analytical precision of tandem mass spectrometry, LC-MS/MS enables accurate detection and quantification of diverse biomarkers, therapeutic drugs, and metabolites in complex biological matrices. Key features such as multiplex testing, broad analyte detection capabilities, and reduced matrix interference make LC-MS/MS an indispensable tool for modern clinical diagnostics. The review highlights the technique's transformative impact on laboratory workflows, its role in improving diagnostic accuracy, and its potential to address emerging challenges in personalized medicine.

## Introduction

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) has emerged as a powerful analytical technique in clinical diagnostics, revolutionizing the field with its exceptional sensitivity, specificity, and versatility [1]. This review article aims to provide a comprehensive overview of the latest advancements and applications of LC-MS/MS in clinical diagnostics, highlighting its growing importance in laboratory medicine and patient care.LC-MS/MS combines the separation capabilities of liquid chromatography with the analytical power of tandem mass spectrometry, offering unique advantages for clinical applications. The technique provides high sensitivity and specificity, the ability to perform multiplex testing, a wide range of analyte detection, and reduced interference from matrix effects [2]. These features make LC-MS/MS particularly suitable for detecting and quantifying various biomarkers, therapeutic drugs, and metabolites in biological samples.

**Table 1:** Applications of LC-MS/MS in Clinical Diagnostics [3].

| Application Area | Examples |
|---|---|
| **Proteomics** | Biomarker discovery in blood, urine, and tissue samples |
| **Metabolomics** | Analysis of metabolites for disease diagnosis and monitoring |
| **Lipidomics** | Comprehensive analysis of lipid profiles |
| **Steroid Analysis** | Diagnosis of endocrine disorders (e.g., primary aldosteronism) |

| | |
|---|---|
| **Therapeutic Drug Monitoring** | Measurement of drug levels in patient samples |
| **Vitamin Analysis** | Quantification of vitamins in biological fluids |
| **Amino Acid Analysis** | Screening for metabolic disorders |
| **Peptide/Protein Analysis** | Quantification of specific proteins or peptide biomarkers |

## Current Applications in Clinical Diagnostics




**Figure 1:** Applications of mass spectrometry in precision medicine. The process involves analyzing patient-derived metabolomes, proteomes, and genomes to aid in diagnosis and develop customized treatments such as hormone therapy, chemotherapy, targeted radionuclide therapy, and biological therapies. Features include high specificity, sensitivity, versatility, and multiplexing capabilities [4].

*Small Molecule Detection*

LC-MS/MS excels in the analysis of small molecules, offering substantial benefits in various clinical areas such as clinical toxicology, endocrinology, inborn errors of metabolism (IEM), and therapeutic drug monitoring (TDM) [5]. The technique's ability to provide analytical sensitivity and selectivity makes it ideal for tackling the challenges posed by diverse sample types and volumes in clinical laboratories.

**Table 2:** Performance Metrics of LC-MS/MS for Primary Aldosteronism Diagnosis [6]

| **Metric** | **Value (95% CI)** |
|---|---|
| Pooled Sensitivity | 0.89 (0.83-0.93) |
| Pooled Specificity | 0.87 (0.82-0.91) |
| Diagnostic Odds Ratio | 55 (28-110) |
| AUC of SROC | 0.94 (0.92-0.96) |
| ARR Diagnostic Odds Ratio | 121.65 (36.28-407.98) |

| | |
|---|---|
| PAC Diagnostic Odds Ratio | 49.85 (24.87-99.93) |

*Steroid Hormone Analysis*

LC-MS/MS has become the gold standard for steroid hormone analysis, offering improved accuracy and specificity compared to traditional immunoassays. The technique allows for simultaneous quantification of multiple steroids, detection of low-abundance steroids, and differentiation between structurally similar compounds [7].

*Vitamin D Assay*

LC-MS/MS has significantly improved vitamin D testing in clinical settings. The technique offers accurate quantification of 25-hydroxyvitamin D (25-OH-D), differentiation between vitamin D2 and D3 metabolites, and detection of other vitamin D metabolites [8].

*Newborn Screening*

LC-MS/MS has revolutionized newborn screening programs, enabling the simultaneous detection of multiple inborn errors of metabolism from a single dried blood spot. This approach allows for early detection of rare genetic disorders, expanded screening panels, and reduced false-positive rates [9].

*Therapeutic Drug Monitoring*

LC-MS/MS has become an essential tool in therapeutic drug monitoring, offering advantages over traditional immunoassays. The technique provides accurate quantification of drug concentrations, detection of drug metabolites, and multiplexed analysis of multiple drugs [10].




**Figure 2:** Overview of developments in MS-based proteomics, highlighting the integration of sample preparation, MS technologies, and bioinformatics tools to generate high-quality clinical and epidemiological data. Advantages include high sensitivity, multiplexing capacity,

and cost-effectiveness, while challenges involve standardization, automation, skilled personnel requirements, and high capital costs [11].

**Table 3:** Advantages and Limitations of LC-MS/MS in Clinical Diagnostics [12].

| Advantages | Limitations |
|---|---|
| High sensitivity and specificity | Complex sample preparation |
| Multiplexing capabilities | High initial equipment cost |
| Rapid analysis (2-5 minutes per test) | Requires specialized personnel |
| Wide dynamic range | Method development can be time-consuming |
| Ability to quantify multiple analytes simultaneously | Potential for matrix effects |
| Improved accuracy over immunoassays | Standardization challenges between laboratories |

**Emerging Trends and Advancements in LC-MS/MS for Clinical Diagnostics**

The field of liquid chromatography-tandem mass spectrometry (LC-MS/MS) is rapidly evolving, with several emerging trends and advancements that are shaping the future of clinical diagnostics. These developments are aimed at improving the efficiency, accessibility, and applicability of LC-MS/MS in clinical settings [13].

*Automation and Integration*

Recent developments in LC-MS/MS technology have focused on improving automation and integration to meet the demanding requirements of clinical laboratories. These advancements are crucial for enhancing the efficiency and reliability of LC-MS/MS in routine clinical use [14].

*Modular Automation for Sample Preparation*

One of the most significant advancements in LC-MS/MS automation is the development of modular systems for sample preparation. These systems can handle various sample types and volumes, performing tasks such as protein precipitation, liquid-liquid extraction, and solid-phase extraction with minimal human intervention [15]. This automation not only reduces the potential for human error but also significantly increases sample throughput. For instance, the Tecan AC Extraction Plate™ has been developed as an automation-friendly sample preparation device for LC-MS/MS analysis. This plate allows for the simultaneous preparation of up to 96 samples, significantly reducing processing time and improving workflow efficiency [16].

*Improved Sample Handling and Prioritization*

Advanced LC-MS/MS systems now incorporate intelligent sample handling and prioritization features. These systems can automatically manage sample queues, allowing for the insertion of urgent samples without disrupting ongoing analyses. This capability is particularly valuable in clinical settings where rapid turnaround times for critical samples can significantly impact patient care [17].

*Increased Throughput and Reduced Turnaround Times*

The integration of high-speed chromatography with rapid scanning mass spectrometers has led to substantial improvements in analytical throughput. Some modern LC-MS/MS systems can analyze hundreds of samples per day, with run times as short as a few minutes per sample [18]. This increased speed, combined with automated sample preparation and data processing, has significantly reduced turnaround times for clinical tests [19].

*Miniaturization and Point-of-Care Testing*

The development of miniature MS systems is driving the potential for clinical integration at the point of care (POC). These systems offer several advantages that could revolutionize on-site clinical testing [20].

*Reduced Size and Cost*

Miniaturized MS systems, often referred to as "MS-on-a-chip," have significantly reduced footprints compared to traditional LC-MS/MS instruments. Some prototypes are as small as a shoebox, making them suitable for use in small clinical labs or even at the bedside [21]. The reduced size often translates to lower manufacturing costs, potentially making MS technology more accessible to smaller healthcare facilities.

*Improved Portability*

The compact nature of miniaturized MS systems greatly enhances their portability. This feature opens up new possibilities for field-based testing, mobile clinics, and rapid response in emergency situations. For example, a portable MS system could be used for on-site drug testing in addiction treatment centers or for rapid diagnosis in remote areas with limited access to central laboratories [22].

*Potential for Rapid, On-Site Testing*

Miniature MS systems have the potential to provide rapid, on-site testing for a variety of clinical applications. These could include therapeutic drug monitoring, toxicology screening, and biomarker detection. The ability to obtain results within minutes rather than hours or days could significantly impact clinical decision-making and patient outcomes [23].

*Imaging Mass Spectrometry*

Matrix-assisted laser desorption ionization (MALDI) imaging MS is an emerging technology that offers unmatched sensitivity and specificity for mapping molecules within tissues. This technique is opening up new possibilities in clinical diagnostics and research [24].

*Comprehensive Molecular Imaging of Biopsies*

MALDI imaging MS allows for the comprehensive molecular analysis of tissue samples without the need for specific staining or labeling. This technique can simultaneously detect and map the distribution of hundreds of molecules, including proteins, peptides, lipids, and metabolites, within a single tissue section. In clinical diagnostics, this capability could provide a more detailed understanding of disease processes and help in identifying new biomarkers [25].

*Histology-Directed Analysis of Specific Tissue Sections*

MALDI imaging MS can be combined with traditional histological techniques to perform targeted analysis of specific tissue regions. This approach, known as histology-directed imaging MS, allows for the correlation of molecular profiles with specific morphological features. In cancer diagnostics, for example, this technique could be used to analyze the molecular composition of tumor margins or to identify regions of tumor heterogeneity [26].

*Spatial Molecular Profiling for Patient Diagnosis and Prognosis*

The ability of MALDI imaging MS to provide spatial information about molecular distributions within tissues makes it a powerful tool for patient diagnosis and prognosis. In oncology, for instance, the spatial distribution of certain proteins or metabolites within a tumor could provide valuable information about tumor aggressiveness or potential treatment response [27].

**Case Studies and Success Stories in LC-MS/MS Clinical Applications**

The application of liquid chromatography-tandem mass spectrometry (LC-MS/MS) in clinical diagnostics has led to numerous success stories across various medical fields. These case studies demonstrate the technique's versatility, accuracy, and potential to revolutionize patient care [28]. This section will explore three significant applications of LC-MS/MS in clinical settings: cardiovascular drug monitoring, antimicrobial therapeutic drug monitoring, and baricitinib monitoring in pediatric patients [29].

**Cardiovascular Drug Monitoring**

Cardiovascular diseases remain a leading cause of mortality worldwide, and proper medication management is crucial for patient outcomes. The work of Dias et al. represents a significant advancement in this area, showcasing the power of LC-MS/MS in comprehensive therapeutic

drug monitoring for cardiovascular patients [30].

*Method Development*

Dias and colleagues developed an LC-MS/MS method capable of simultaneously detecting 34 commonly prescribed cardiovascular medications or their metabolites using only 100 µl of serum or plasma [31]. This method is particularly noteworthy for its ability to monitor 67 different drug types, including:

1. Anticoagulants
2. Angiotensin-converting enzyme (ACE) inhibitors
3. Beta-blockers
4. Calcium channel blockers
5. Statins

The development of this method involved several key steps:

Sample Preparation: The researchers optimized a simple protein precipitation procedure using acetonitrile, which effectively removed interfering compounds while maintaining high analyte recovery [32].

Chromatographic Separation: A reverse-phase UHPLC column was employed, with a gradient elution using water and acetonitrile, both containing 0.1% formic acid. This setup allowed for efficient separation of the diverse range of analytes.

Mass Spectrometry: The team used a triple quadrupole mass spectrometer operating in multiple reaction monitoring (MRM) mode, which provided high sensitivity and selectivity for each target compound.

Method Validation: The method was rigorously validated according to FDA guidelines, demonstrating excellent linearity, accuracy, precision, and stability for all analytes [33].

*Clinical Significance*

The method developed by Dias et al. offers several significant advantages for clinical practice:

1. Comprehensive Coverage: By monitoring 67 drug types with a single assay, this method provides a comprehensive overview of a patient's cardiovascular medication profile. This is particularly valuable for patients on multiple medications, as it allows clinicians to assess potential drug interactions and adherence to prescribed regimens [34].
2. Minimal Sample Volume: The ability to perform this comprehensive analysis using only 100 µl of serum or plasma is a significant advantage, especially for patients who require frequent monitoring or have limited blood volume available for testing [35].
3. Rapid Analysis: The LC-MS/MS method allows for relatively quick analysis times, enabling faster turnaround of results compared to traditional methods [36]. This can lead to more timely clinical decision-making and adjustments to patient care.
4. High Specificity: The use of LC-MS/MS provides high specificity for each analyte, reducing the risk of interferences that can plague other analytical methods, such as immunoassays [37].
5. Potential for Personalized Medicine: By accurately quantifying drug levels, this method supports the practice of personalized medicine, allowing clinicians to tailor drug dosages based on individual patient metabolism and response [38].

**Table 4:** summarizing advanced and latest LC-MS/MS applications across various clinical specializations: [39]

| Specialization | Application | Specific Data |
|---|---|---|
| **Immunology** | Quantification of monoclonal antibodies | LLOQ of 0.1 Âµg/ml for trastuzumab and bevacizumab; 0.25 Âµg/ml for adalimumab |
| **Oncology** | ADC bioanalysis | Simultaneous detection of total antibodies, antibody conjugates, coupled drugs, and free drugs in a single sample |
| **Cardiovascular** | Biomarker discovery for atherosclerosis | Upregulation of taurocholic acid, cholic acid, cortisol, hypoxanthine, TMAO, and isoleucine in patient serum |
| **Neurology** | Metabolomics for neurological disorders | Not specified in the search results |
| **Urology** | Analysis of urinary metabolites | Not specified in the search results |
| **Hepatology** | Bile acid profiling | Higher levels of deoxycholic acid (DCA) and taurodeoxycholic acid (TDCA) in T2DM patients with subclinical atherosclerosis |
| **Endocrinology** | Steroid analysis | Diagnosis of endocrine disorders like primary aldosteronism |
| **Metabolomics** | Diabetic cardiomyopathy biomarker discovery | Distinct metabolite profiles identified in plasma of DCM patients |
| **Toxicology** | Multi-component analysis of drugs and poisons | Applied in environmental, forensic, and clinical toxicology |
| **Pediatrics** | Newborn screening for metabolic disorders | Not specified in the search results |
| **Microbiology** | Rapid microbial identification | Mentioned as an application, but no specific data provided |

The success of this comprehensive cardiovascular drug monitoring method opens up several avenues for future research and clinical application:

The principles used in this method could be applied to develop similar comprehensive panels for other therapeutic areas, such as neurological or oncological drugs. Incorporating these comprehensive drug monitoring results into electronic health records could provide clinicians with a more complete picture of a patient's medication status and history [40]. The method's ability to simultaneously quantify multiple drugs and metabolites could be valuable in pharmacokinetic studies, helping to elucidate drug-drug interactions and individual variations in drug metabolism.

**Antimicrobial Therapeutic Drug Monitoring**

The appropriate use of antimicrobial drugs is critical in managing infections, particularly in critically ill patients [41]. The work of Gao et al. demonstrates the potential of LC-MS/MS in improving antimicrobial therapeutic drug monitoring (TDM), which can lead to more effective and personalized treatment strategies [42].

**Method Development**

Gao and colleagues developed an LC-MS/MS method for the simultaneous quantification of multiple antimicrobial drugs, including pyrazinamide, isoniazid, ethambutol, streptomycin, and rifampicin. The method development process involved several key steps:

**Sample Preparation**

Tuberculosis treatment monitoring: In a multi-drug resistant tuberculosis (MDR-TB) clinic, the simple protein precipitation method using methanol allows for rapid processing of numerous patient samples. This enables clinicians to adjust dosages of pyrazinamide and isoniazid

quickly, ensuring optimal drug concentrations are maintained throughout the lengthy treatment course [43].

Pediatric sepsis management: In a pediatric intensive care unit, the efficient sample preparation technique requires only small volumes of blood from critically ill infants. This allows for frequent monitoring of streptomycin levels without risking iatrogenic anemia, enabling precise dose adjustments in this vulnerable population[44] .

**Chromatographic Separation**

Complex drug interactions in HIV/TB coinfection: For a patient with HIV/TB coinfection on multiple medications, the reverse-phase HPLC column with gradient elution effectively separates rifampicin from antiretroviral drugs. This allows clinicians to accurately monitor rifampicin levels and adjust dosages to prevent subtherapeutic concentrations due to drug-drug interactions [45].

Personalized dosing in renal impairment: In a patient with severe renal impairment requiring ethambutol therapy, the efficient chromatographic separation allows for precise quantification of ethambutol levels. This enables nephrologists and infectious disease specialists to collaborate on personalized dosing regimens that maintain therapeutic efficacy while minimizing the risk of ethambutol-induced optic neuropathy [46].

**Mass Spectrometry**

Rapid diagnosis of antimicrobial resistance: In a case of suspected drug-resistant tuberculosis, the high sensitivity of the triple quadrupole mass spectrometer operating in MRM mode allows for detection of subtherapeutic levels of isoniazid and rifampicin in a patient's serum. This rapid identification of potential resistance enables prompt adjustment of the treatment regimen, improving patient outcomes [47].

Optimizing combination therapy: For a critically ill patient with a polymicrobial infection, the selectivity of the MRM mode allows for simultaneous monitoring of multiple antimicrobials (e.g., streptomycin and rifampicin) without interference. This enables fine-tuning of the combination therapy to achieve synergistic effects while minimizing toxicity risks [48].

**Method Validation**

Multi-center clinical trial support: The rigorously validated method, demonstrating excellent linearity, accuracy, precision, and stability, is employed in a multi-center clinical trial evaluating a novel regimen for drug-resistant tuberculosis. The robust validation ensures consistent and reliable results across different research sites, strengthening the trial's conclusions [49].

Forensic toxicology application: In a case of suspected antimicrobial poisoning, the validated method's high accuracy and precision provide legally defensible quantification of multiple antimicrobials in postmortem samples. This assists medical examiners in determining the cause of death and supports potential legal proceedings [50].

The development of this LC-MS/MS method for simultaneous quantification of multiple antimicrobial drugs represents a significant advancement in therapeutic drug monitoring capabilities. By enabling the accurate and rapid measurement of several important antibiotics in a single analytical run, this method addresses key challenges in antimicrobial stewardship and personalized medicine [51].

The optimized sample preparation technique, utilizing a simple protein precipitation method with methanol, offers several advantages in clinical settings. Its simplicity and speed allow for high-throughput processing of patient samples, which is crucial in busy hospital laboratories. Moreover, the efficient extraction maintains high analyte recovery while effectively removing interfering compounds, ensuring reliable results even in complex biological matrices [52].

The chromatographic separation, employing a reverse-phase HPLC column with a carefully optimized gradient elution, demonstrates the power of modern liquid chromatography techniques. By achieving efficient separation of structurally diverse antimicrobial compounds,

this method overcomes one of the primary challenges in multi-analyte assays [53]. The ability to resolve closely eluting peaks and minimize matrix effects contributes significantly to the overall accuracy and precision of the method.

The use of a triple quadrupole mass spectrometer operating in multiple reaction monitoring (MRM) mode represents the state-of-the-art in quantitative bioanalysis [54]. This approach provides unparalleled sensitivity and selectivity, allowing for accurate quantification of antimicrobials even at low concentrations. The specificity of MRM transitions for each target compound minimizes the risk of interference from other drugs or endogenous substances, a critical factor in analyzing samples from patients on complex medication regimens [55].

The rigorous validation of the method according to FDA guidelines ensures its reliability and applicability in various clinical and research settings. The demonstrated excellent linearity, accuracy, precision, and stability for all analytes provide confidence in the results obtained using this method. This is particularly important in therapeutic drug monitoring, where clinical decisions are based on the reported concentrations [56].

The real-world applications of this method are diverse and impactful. In tuberculosis treatment, where long-term multi-drug regimens are the norm, the ability to simultaneously monitor levels of drugs like pyrazinamide, isoniazid, and rifampicin can significantly improve patient care. Clinicians can quickly identify suboptimal drug levels, whether due to poor absorption, drug-drug interactions, or non-adherence, and make timely adjustments to the treatment plan [57].

For critically ill patients, particularly those with complex infections or organ dysfunction, this method offers the potential for truly personalized antimicrobial therapy. By providing rapid and accurate measurements of multiple drug levels, it enables clinicians to optimize dosing regimens based on individual patient pharmacokinetics [58]. This is especially valuable in populations with altered drug metabolism or clearance, such as those with renal or hepatic impairment, where standard dosing recommendations may be inadequate.

The method's applicability extends beyond routine clinical care to support research and drug development efforts. In clinical trials of new antimicrobial regimens, the ability to accurately quantify multiple drugs simultaneously can provide valuable pharmacokinetic data, helping to establish optimal dosing strategies and identify potential drug-drug interactions [59].

Furthermore, the validated method's high sensitivity and specificity make it valuable in forensic toxicology applications, where precise quantification of antimicrobials may be required in legal contexts [60].

As antimicrobial resistance continues to pose a global health threat, tools that enable more precise and personalized use of existing antibiotics become increasingly crucial. This LC-MS/MS method represents a significant step forward in antimicrobial stewardship efforts, providing clinicians and researchers with a powerful tool to optimize antimicrobial therapy, minimize toxicity, and potentially slow the development of resistance [61].

In conclusion, the LC-MS/MS method developed by Gao and colleagues for the simultaneous quantification of multiple antimicrobial drugs demonstrates the potential of advanced analytical techniques to transform therapeutic drug monitoring. By enabling rapid, accurate, and comprehensive assessment of antimicrobial levels, this method paves the way for more effective, personalized, and responsible use of these critical medications in the fight against infectious diseases [62].

**Clinical Significance**

The LC-MS/MS method developed by Gao et al. offers several important advantages for antimicrobial TDM: [63]

1. Rapid Analysis: The method provides quick turnaround times, allowing for near real-time monitoring of drug levels. This is particularly crucial in critically ill patients, where timely adjustments to antimicrobial therapy can significantly impact outcomes.

2. Simultaneous Quantification: The ability to measure multiple antimicrobials in a single run is especially valuable in patients receiving combination therapy, allowing clinicians to monitor and optimize complex treatment regimens.
3. High Sensitivity and Specificity: The LC-MS/MS method offers superior sensitivity and specificity compared to traditional immunoassays, reducing the risk of interferences and false results.
4. Minimal Sample Volume: The method requires only a small volume of plasma, which is beneficial for patients requiring frequent monitoring or those with limited blood volume available for testing.
5. Support for Personalized Medicine: By accurately quantifying antimicrobial levels, this method supports the practice of personalized medicine, allowing clinicians to tailor drug dosages based on individual patient pharmacokinetics and response.

The study by Gao et al. demonstrated that LC-MS/MS could provide rapid and accurate results, making it suitable for real-time TDM-guided personalized antimicrobial treatment in critically ill patients. This approach has several potential benefits: [64]

*Improved Treatment Efficacy:* By ensuring that antimicrobial concentrations remain within the therapeutic range, clinicians can maximize treatment efficacy while minimizing the risk of toxicity.

*Reduced Antimicrobial Resistance:* Optimal dosing based on TDM can help prevent the development of antimicrobial resistance by ensuring that pathogens are exposed to effective drug concentrations [65].

*Cost-Effectiveness:* While LC-MS/MS equipment represents a significant initial investment, the ability to simultaneously measure multiple drugs and the potential for improved patient outcomes could lead to long-term cost savings.

Future application of LC-MS/MS in antimicrobial TDM include:

*Expansion to Other Antimicrobials:* The principles used in this method could be applied to develop similar panels for other classes of antimicrobials, providing comprehensive coverage for a wide range of infections.

*Integration with Clinical Decision Support Systems:* Incorporating LC-MS/MS TDM results into clinical decision support systems could help guide antimicrobial therapy in real-time, improving patient care [66].

*Pharmacokinetic/Pharmacodynamic Studies:* The method's ability to provide accurate and timely drug level measurements could be valuable in conducting pharmacokinetic/pharmacodynamic studies to optimize dosing regimens for different patient populations.

**Baricitinib Monitoring in Pediatric Patients**

Baricitinib, a Janus kinase (JAK) inhibitor, has shown promise in treating various inflammatory conditions, including rheumatoid arthritis and more recently, severe COVID-19. The work of Cafaro et al. in developing an LC-MS/MS method for baricitinib quantification in pediatric patients represents an important step in optimizing the use of this drug in a vulnerable population [67].

*Method Development*

Cafaro and colleagues developed an LC-MS/MS method for the quantification of baricitinib in pediatric patients. The method demonstrated several key features as discussed:

The method was capable of accurately quantifying baricitinib from a small plasma sample of only 50 µl. This is particularly important in pediatric patients, where blood volume for testing is often limited [68]. The method showed excellent reliability and reproducibility without significant matrix effects, ensuring consistent results across different samples and analytical

runs and demonstrated a linear response across a wide concentration range (1.024-100 ng/ml), allowing for accurate quantification of baricitinib at both low and high therapeutic levels [69].
*The method development process involved several critical steps:*

1. Sample Preparation: The researchers optimized a liquid-liquid extraction procedure using ethyl acetate, which effectively isolated baricitinib from plasma while minimizing matrix effects [70].
2. Chromatographic Separation: A reverse-phase UHPLC column was employed with a gradient elution using water and acetonitrile, both containing 0.1% formic acid. This setup allowed for efficient separation of baricitinib from potential interfering compounds.
3. Mass Spectrometry: The team used a triple quadrupole mass spectrometer operating in multiple reaction monitoring (MRM) mode, which provided high sensitivity and selectivity for baricitinib.
4. Method Validation: The method was rigorously validated according to FDA and EMA guidelines, demonstrating excellent linearity, accuracy, precision, and stability.

*Clinical Significance*
The LC-MS/MS method developed by Cafaro et al. offers several important advantages for baricitinib monitoring in pediatric patients:
Pediatric-Friendly Sampling
Minimally invasive monitoring in JIA: For a 7-year-old patient with juvenile idiopathic arthritis (JIA) receiving baricitinib, the ability to measure drug levels from just 50 µL of plasma allows for frequent monitoring without causing undue stress or anemia. This is particularly beneficial during the initial dose titration phase, where multiple samples may be needed to optimize therapy [71].
Neonatal drug monitoring: In a case of a 3-week-old infant with a rare interferon-mediated autoinflammatory disorder treated with baricitinib under compassionate use, the low sample volume requirement enables regular drug level checks without compromising the baby's health or necessitating blood transfusions [72].
**High Sensitivity and Specificity**
*Detecting subtherapeutic levels:* A 12-year-old patient with atopic dermatitis shows poor response to baricitinib therapy. The highly sensitive LC-MS/MS method reveals unexpectedly low trough levels of 1.5 ng/mL, suggesting potential issues with medication adherence or absorption that might have been missed by less sensitive assays [73].
*Avoiding drug interactions:* In a 15-year-old liver transplant recipient prescribed baricitinib for refractory graft-versus-host disease, the specific LC-MS/MS method accurately quantifies baricitinib levels despite the presence of multiple immunosuppressants and antibiotics, allowing for precise dose adjustments to maintain therapeutic efficacy while minimizing toxicity risks [74].
**Wide Quantification Range**
*Dose escalation in severe disease*: A 16-year-old with treatment-resistant alopecia areata starts baricitinib at a standard dose, but requires gradual dose increases. The wide quantification range of 1.024-100 ng/mL allows for accurate monitoring throughout the dose escalation process, from initial low doses to higher therapeutic levels, ensuring safety and efficacy at each step [75].
*Monitoring high-dose pulse therapy:* In a clinical trial exploring high-dose pulse baricitinib therapy for pediatric lupus, the broad quantification range enables accurate measurement of both trough levels during standard dosing and peak levels during pulse administration, providing crucial pharmacokinetic data to guide this novel treatment approach [76].

**Potential for Personalized Medicine**

*Pharmacogenomic-guided dosing:* A 9-year-old patient with JIA is found to have a genetic variant affecting JAK inhibitor metabolism. By precisely quantifying baricitinib levels, clinicians can adjust the dose to achieve optimal therapeutic exposure despite the patient's altered drug metabolism, maximizing efficacy while minimizing side effects [77].

*Tailoring therapy in obesity:* For a 14-year-old patient with severe atopic dermatitis and obesity, standard weight-based dosing of baricitinib leads to suboptimal response. Accurate drug level monitoring allows for personalized dose adjustments, accounting for the patient's altered pharmacokinetics due to increased body mass, and ultimately achieving better disease control [78].

The LC-MS/MS method developed by Cafaro et al. represents a significant advancement in therapeutic drug monitoring for baricitinib in pediatric populations. Its ability to accurately quantify drug levels from small plasma volumes addresses a critical need in pediatric pharmacology, where minimizing blood draw volumes is paramount. This is especially important for young children and infants, where frequent blood sampling can lead to iatrogenic anemia and increased stress [79].

The high sensitivity and specificity of the method offer several clinical advantages. In cases of suspected non-adherence or malabsorption, the ability to detect even very low levels of baricitinib can provide valuable insights into the cause of treatment failure. This is particularly relevant in adolescent populations, where medication adherence can be challenging [80]. Additionally, the method's specificity ensures accurate quantification even in complex clinical scenarios, such as patients on multiple medications or those with altered drug metabolism due to organ dysfunction or genetic variations.

The wide quantification range (1.024-100 ng/mL) of the assay is well-suited to cover the expected therapeutic range of baricitinib across various pediatric indications and age groups. This broad range allows for monitoring during dose titration, from initial low doses in young children to potentially higher doses used in adolescents or in cases of severe disease. It also enables accurate quantification during pharmacokinetic studies exploring novel dosing strategies, such as high-dose pulse therapy, which may be investigated for rapid disease control in certain conditions [81].

Perhaps the most significant impact of this LC-MS/MS method is its potential to facilitate personalized medicine approaches in pediatric rheumatology and dermatology. By providing precise measurements of drug exposure, clinicians can move beyond standard weight-based dosing to truly individualized treatment plans [82]. This is particularly important in pediatric populations, where factors such as growth, puberty, and developmental changes can significantly impact drug pharmacokinetics and pharmacodynamics.

For example, in patients with genetic variants affecting drug metabolism, the ability to accurately measure baricitinib levels allows for dose adjustments that compensate for altered drug clearance. Similarly, in patients with extreme body compositions (e.g., obesity or severe malnutrition), standard dosing may lead to under- or over-exposure. Precise therapeutic drug monitoring enables clinicians to optimize dosing for these complex cases, potentially improving treatment outcomes and reducing the risk of adverse effects [83].

The method's application extends beyond individual patient care to support critical research in pediatric pharmacology. By enabling accurate pharmacokinetic studies in diverse pediatric populations, it can help establish evidence-based dosing guidelines for different age groups and clinical conditions [84]. This is particularly valuable for newer drugs like baricitinib, where pediatric data may be limited compared to adult populations.

Furthermore, the ability to accurately quantify baricitinib levels opens up possibilities for more sophisticated approaches to treatment optimization. For instance, future research could explore correlations between drug levels and specific biomarkers of disease activity or drug response.

This could lead to the development of therapeutic algorithms that consider both drug exposure and pharmacodynamic effects, further refining the personalized medicine approach [85].

As the use of JAK inhibitors like baricitinib expands in pediatric medicine, encompassing not only rheumatologic and dermatologic conditions but also potential applications in rare diseases and even COVID-19, the importance of accurate therapeutic drug monitoring grows [86]. This LC-MS/MS method provides a powerful tool to support both clinical care and research initiatives, ultimately contributing to safer and more effective use of baricitinib in pediatric populations.

In conclusion, the LC-MS/MS method developed by Cafaro et al. represents a significant advancement in pediatric therapeutic drug monitoring for baricitinib [87]. Its combination of pediatric-friendly sampling, high sensitivity and specificity, wide quantification range, and potential to support personalized medicine approaches makes it a valuable asset in the clinical management of children and adolescents receiving this medication. As we continue to refine our understanding of JAK inhibitor use in pediatric populations, precise analytical methods like this will play a crucial role in optimizing treatment strategies and improving patient outcomes [88].

**Clinical Impact**

This innovative LC-MS/MS technique for baricitinib monitoring in pediatric patients has significant potential to impact clinical practice and future research:

*Optimized Dosing*

Personalized dosing for JIA-uveitis: In the JUVE-BRIGHT trial, clinicians can use the LC-MS/MS method to adjust baricitinib doses for pediatric patients with juvenile idiopathic arthritis-associated uveitis or chronic ANA-positive uveitis [89]. This allows for precise tailoring of treatment based on individual patient pharmacokinetics, potentially improving efficacy and reducing side effects.

Age-specific dosing for COVID-19: The FDA's Emergency Use Authorization for baricitinib in pediatric COVID-19 patients recommends different doses based on age groups. The LC-MS/MS method can help refine these recommendations by providing accurate plasma level data across various age ranges, ensuring optimal therapeutic effects while minimizing risks [90].

*Improved Safety Monitoring*

Detecting drug accumulation in renal impairment: For pediatric patients with reduced renal function, the LC-MS/MS method can be used to closely monitor baricitinib levels. This is particularly important given the dosage modifications recommended for patients with eGFR <90 mL/min/1.73 m2, allowing for early detection of potential drug accumulation and toxicity [91].

Managing drug interactions: In cases where baricitinib is used in combination with other medications, such as methotrexate for JIA, the LC-MS/MS method can help assess the impact of these drug interactions on baricitinib levels. This enables clinicians to make informed decisions about dose adjustments or alternative treatments [92].

**Support for Clinical Trials**

Pharmacokinetic studies in rare diseases: The LC-MS/MS method is being applied to evaluate baricitinib pharmacokinetics in pediatric patients with rare Mendelian autoinflammatory diseases characterized by type I interferon-mediated damage. This data will be crucial for establishing appropriate dosing regimens in these understudied populations [93].

Dose-response relationships in atopic dermatitis: In ongoing trials of baricitinib for pediatric atopic dermatitis, the LC-MS/MS method can provide precise measurements of drug exposure. This data can be correlated with clinical outcomes to establish clear dose-response relationships, informing optimal dosing strategies for different severity levels of the disease.

**Challenges in LC-MS/MS**

Despite its numerous advantages, LC-MS/MS still faces several challenges in widespread clinical adoption. These include the need for improved standardization and harmonization of methods across different laboratories, simplification of sample preparation processes, expansion of test menus, and increased training and education for laboratory personnel [94]. The future of LC-MS/MS in clinical diagnostics may involve the integration of artificial intelligence (AI) and machine learning (ML) algorithms to improve data analysis and interpretation, enhance pattern recognition for biomarker discovery, and develop predictive models for disease diagnosis and prognosis.In conclusion, LC-MS/MS has emerged as a powerful analytical tool in clinical diagnostics, offering unparalleled sensitivity, specificity, and versatility [95]. As the technology continues to evolve, LC-MS/MS is poised to play an increasingly important role in personalized medicine, enabling more accurate diagnosis, prognosis, and treatment monitoring. Addressing the remaining challenges through continued research, development, and education will be crucial for realizing the full potential of LC-MS/MS in clinical diagnostics [96].

**Future Directions**

*Expansion to Other JAK Inhibitors*

Multi-drug assays for rheumatologic conditions: Develop an LC-MS/MS panel capable of simultaneously measuring baricitinib, tofacitinib, and upadacitinib levels. This would be valuable for clinicians managing pediatric patients with various rheumatologic conditions, allowing for easy comparison and potential switching between JAK inhibitors based on individual response.

Comparative pharmacokinetics in dermatology: Create an assay to measure both baricitinib and abrocitinib, two JAK inhibitors used in atopic dermatitis. This would enable direct comparisons of drug levels and exposure in pediatric patients, potentially guiding treatment selection and optimization.

*Integration with Pharmacodynamic Markers*

Cytokine profiling in JIA: Combine baricitinib level measurements with assessments of key inflammatory cytokines like IL-6 and TNF-α in juvenile idiopathic arthritis patients. This integrated approach could provide a more comprehensive picture of treatment efficacy and help identify early markers of response or resistance.

Interferon signature monitoring: For pediatric patients with interferon-mediated autoinflammatory diseases, pair baricitinib level measurements with assessments of interferon-stimulated gene expression. This could help determine the optimal drug levels needed to effectively suppress interferon signaling in different patient subgroups.

*Long-term Safety Studies*

Growth and development assessment: Use the LC-MS/MS method to track long-term baricitinib exposure in pediatric patients with chronic conditions like atopic dermatitis or JIA. Correlate drug levels with growth parameters, pubertal development, and bone density measurements to evaluate any potential impacts on these crucial developmental processes.

Infection risk stratification: In extended safety studies, combine baricitinib level monitoring with assessments of immune function markers. This could help identify whether certain threshold levels of drug exposure are associated with increased risk of serious infections, allowing for more personalized risk-benefit assessments in long-term use.

These advancements in LC-MS/MS applications for baricitinib monitoring demonstrate the technique's potential to significantly improve personalized medicine approaches in pediatric rheumatology, dermatology, and beyond. The ability to accurately measure drug levels in small plasma volumes (50 µL) is particularly valuable in pediatric populations, where minimizing blood draw volumes is crucial.

The wide linear range of the assay (1.024–100 ng/mL) covers the expected therapeutic range

for baricitinib in various pediatric indications. This allows for precise quantification of drug levels across different dosing regimens and patient populations, from young children receiving lower doses to adolescents on adult-equivalent dosing.

As baricitinib and other JAK inhibitors continue to find new applications in pediatric medicine, this LC-MS/MS method provides a powerful tool for optimizing treatment strategies. It enables clinicians to move beyond a one-size-fits-all approach to dosing, instead tailoring treatment based on individual patient pharmacokinetics and response.

The potential for integrating drug level measurements with pharmacodynamic markers is particularly exciting. This could lead to the development of more sophisticated therapeutic drug monitoring protocols, where both drug exposure and biological effect are considered in treatment decisions. For example, in a patient with suboptimal response, clinicians could use the combined data to determine whether increasing the dose, switching to a different JAK inhibitor, or adding a complementary therapy would be most appropriate.

Furthermore, the application of this LC-MS/MS method in long-term safety studies will be crucial for establishing the risk-benefit profile of baricitinib in pediatric populations over extended periods. This is especially important given the relatively recent approval of JAK inhibitors for pediatric use and ongoing concerns about potential long-term effects on growth, development, and immune function.

As the technology continues to evolve and become more accessible, LC-MS/MS is likely to play an increasingly central role in pediatric clinical pharmacology and decision-making processes. The ability to rapidly and accurately measure drug levels, combined with advances in pharmacogenomics and biomarker discovery, paves the way for truly personalized medicine approaches in complex pediatric conditions.

In conclusion, this innovative LC-MS/MS technique for baricitinib monitoring represents a significant advance in pediatric therapeutic drug monitoring. Its applications span from optimizing individual patient care to supporting critical research that will shape the future use of JAK inhibitors in children. As we continue to expand our understanding of these powerful immunomodulatory drugs, precise analytical methods like this will be essential in maximizing their benefits while minimizing risks in our most vulnerable patients.

**Acknowledgment**

The author is thankful to Mewar University, Chittorgarh for encouragement and support.

**Funding**

None

**Competing interests**

No conflicts of interest

**Ethical approval**

Not required

**Reference :**

1. Seger C, Salzmann L. After another decade: LC–MS/MS became routine in clinical diagnostics. Clinical biochemistry. 2020 Aug 1;82:2-11.

2. Seger C, Salzmann L. After another decade: LC–MS/MS became routine in clinical diagnostics. Clinical biochemistry. 2020 Aug 1;82:2-11.

3. Rischke S, Hahnefeld L, Burla B, Behrens F, Gurke R, Garrett TJ. Small molecule biomarker discovery: Proposed workflow for LC-MS-based clinical research projects. Journal of mass spectrometry and advances in the clinical lab. 2023 Apr 1;28:47-55.

4. Ngere JB, Ebrahimi KH, Williams R, Pires E, Walsby-Tickle J, McCullagh JS. Ion-exchange chromatography coupled to mass spectrometry in life science, environmental, and medical research. Analytical Chemistry. 2023 Jan 10;95(1):152-66.

5. Gill EL, Wang J, Viaene AN, Master SR, Ganetzky RD. Methodologies in mitochondrial testing: diagnosing a primary mitochondrial respiratory chain disorder. Clinical Chemistry.

2023 Jun;69(6):564-82.
6. Junger S, Hoene M, Shipkova M, Danzl G, Schöberl C, Peter A, Lehmann R, Wieland E, Braitmaier H. Automated LC-MS/MS: ready for the clinical routine laboratory?. Journal of Mass Spectrometry and Advances in the Clinical Lab. 2023 Nov 1;30:1-9.
7. Murray DL, Dasari S. Clinical mass spectrometry approaches to myeloma and amyloidosis. Clinics in Laboratory Medicine. 2021 Jun 1;41(2):203-19.
8. Chiu HH, Liao HW, Shao YY, Lu YS, Lin CH, Tsai IL, Kuo CH. Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS/MS. Analytica chimica acta. 2018 Aug 17;1019:93-102.
9. Bogos LG, Pralea IE, Moldovan RC, Iuga CA. Indirect enantioseparations: recent advances in chiral metabolomics for biomedical research. International Journal of Molecular Sciences. 2022 Jul 4;23(13):7428.
10. Pasko BL. Development of a Lipidomics Platform to Discover Enzymatic Activities of Mycobacterial Proteins of Unknown Function (Doctoral dissertation).
11. Smith IR. Developing Proteomic Methods to Assay Function of Proteoforms. University of Washington; 2022.
12. Katsarou EI, Billinis C, Galamatis D, Fthenakis GC, Tsangaris GT, Katsafadou AI. Applied proteomics in 'one health'. Proteomes. 2021 Jun 30;9(3):31.
13. Sumida K, Nadkarni GN, Grams ME, Sang Y, Ballew SH, Coresh J, Matsushita K, Surapaneni A, Brunskill N, Chadban SJ, Chang AR. Conversion of urine protein–creatinine ratio or urine dipstick protein to urine albumin–creatinine ratio for use in chronic kidney disease screening and prognosis: an individual participant–based meta-analysis. Annals of internal medicine. 2020 Sep 15;173(6):426-35.
14. Zhou J, Zhong L. Applications of liquid chromatography-mass spectrometry based metabolomics in predictive and personalized medicine. Frontiers in Molecular Biosciences. 2022 Nov 3;9:1049016.
15. Makowski N, Burckhardt BB. Enabling insights into the maturation of the renin–angiotensin–aldosterone system in children—Development of a low-volume LC–MS assay for the simultaneous determination of aldosterone, its precursor, and main metabolite. Steroids. 2019 Aug 1;148:73-81.
16. Thomas SN, French D, Jannetto PJ, Rappold BA, Clarke WA. Liquid chromatography–tandem mass spectrometry for clinical diagnostics. Nature Reviews Methods Primers. 2022 Dec 8;2(1):96.
17. Song L, Fang F, Liu P, Zeng G, Liu H, Zhao Y, Xie X, Tseng G, Randhawa P, Xiao K. Quantitative proteomics for monitoring renal transplant injury. PROTEOMICS–Clinical Applications. 2020 Jul;14(4):1900036.
18. Borsò M, Agretti P, Zucchi R, Saba A. Mass spectrometry in the diagnosis of thyroid disease and in the study of thyroid hormone metabolism. Mass Spectrometry Reviews. 2022 May;41(3):443-68.
19. Pujić I, Perreault H. Recent advancements in glycoproteomic studies: Glycopeptide enrichment and derivatization, characterization of glycosylation in SARS CoV2, and interacting glycoproteins. Mass spectrometry reviews. 2022 May;41(3):488-507.
20. Militello L, Zhang V. Performance Evaluation of Two FDA-Approved Fentanyl Immunoassays against LC-MS/MS. American Journal of Clinical Pathology. 2022 Nov 1;158(Supplement_1):S45-6.
21. Serafim V, Tiugan DA, Andreescu N, Mihailescu A, Paul C, Velea I, Puiu M, Niculescu MD. Development and validation of a LC–MS/MS-based assay for quantification of free and total omega 3 and 6 fatty acids from human plasma. Molecules. 2019 Jan 20;24(2):360.
22. Pan S, Ding A, Li Y, Sun Y, Zhan Y, Ye Z, Song N, Peng B, Li L, Huang W, Shao H.

Small-molecule probes from bench to bedside: advancing molecular analysis of drug–target interactions toward precision medicine. Chemical Society Reviews. 2023;52(16):5706-43.
23. Thomas SN, French D, Jannetto PJ, Rappold BA, Clarke WA. Liquid chromatography–tandem mass spectrometry for clinical diagnostics. Nature Reviews Methods Primers. 2022 Dec 8;2(1):96.
24. Krotulski AJ, Papsun DM, Kacinko SL, Logan BK. Isotonitazene quantitation and metabolite discovery in authentic forensic casework. Journal of Analytical Toxicology. 2020 Jul 31;44(6):521-30.
25. Omosule C, Blair C, Herries E, Ladenson J, Farnsworth C, Dietzen D, Gaut J. LC/MS-MS quantification of myo-inositol: a novel biomarker for kidney disease. American Journal of Clinical Pathology. 2023 Nov 1;160(Supplement_1):S117-8.
26. Magalhães LM, Rodrigues FA, Quirino-Filho J, Gondim RN, Ribeiro S, K. Sousa J, Clementino M, Maciel BL, Havt A, Santos AA, Magalhães PJ. Measuring lactulose and mannitol levels using liquid chromatography coupled with tandem mass spectrum: application to clinical study of intestinal epithelium barrier function. medRxiv. 2022 Oct 14:2022-10.
27. Yoluç Y. Absolute quantification of exogenous stimuli-induced nucleic acid modification dynamics with LC-MS (Doctoral dissertation, lmu).
28. Zhu M, Yuan L, Wu Y, Chu L, Wang W, Zhang H, Liao W, Peng X, Deng H. Simultaneous LC-MS/MS quantification of glucocorticoids, melatonin and its metabolites in hair. Journal of Chromatography B. 2022 Apr 30;1196:123217.
29. Dekant R, Bertermann R, Serban J, Sharma S, Shinohara M, Morizawa Y, Okamoto H, Brock W, Dekant W, Mally A. Species-differences in the in vitro biotransformation of trifluoroethene (HFO-1123). Archives of Toxicology. 2023 Dec;97(12):3095-111.
30. Dekant R, Bertermann R, Serban J, Sharma S, Shinohara M, Morizawa Y, Okamoto H, Brock W, Dekant W, Mally A. Species-differences in the in vitro biotransformation of trifluoroethene (HFO-1123). Archives of Toxicology. 2023 Dec;97(12):3095-111.
31. White D, O'Halloran S, Salman S, MacQuillan G, Joyce DA. Validation of a liquid chromatography tandem mass spectrometry (LC-MS/MS) method for erythrocyte phosphatidylethanol revealing critical considerations for its use as a clinical biomarker. Journal of Chromatography B. 2022 Mar 1;1192:123134.
32. Valverde Domínguez I. Optimization of toxicological and forensic tools in the investigation of wildlife poisoning. Proyecto de investigación:. 2022 Jan 24.
33. Campos EG. Novel drugs of abuse and bioanalytical strategies in Forensic Toxicology: metabolomics, analysis in blood, urine or DBS and human performance and post mortem cases (Doctoral dissertation, Universidade de São Paulo).
34. Konieczna L, Belka M, Okońska M, Pyszka M, Bączek T. New 3D-printed sorbent for extraction of steroids from human plasma preceding LC–MS analysis. Journal of Chromatography A. 2018 Apr 13;1545:1-1.
35. Lanzillotta M, Mancuso G, Della-Torre E. Advances in the diagnosis and management of IgG4 related disease. Bmj. 2020 Jun 16;369.
36. Lima NM, Fernandes BL, Alves GF, de Souza JC, Siqueira MM, do Nascimento MP, Moreira OB, Sussulini A, de Oliveira MA. Mass spectrometry applied to diagnosis, prognosis, and therapeutic targets identification for the novel coronavirus SARS-CoV-2: A review. Analytica chimica acta. 2022 Feb 22;1195:339385.
37. Šimková M, Kolátorová L, Drašar P, Vítků J. An LC-MS/MS method for the simultaneous quantification of 32 steroids in human plasma. Journal of Chromatography B. 2022 Jun 30;1201:123294.
38. Izhar R, Borriello M, La Russa A, Di Paola R, De A, Capasso G, Ingrosso D, Perna AF, Simeoni M. Fabry disease in women: genetic basis, available biomarkers, and clinical manifestations. Genes. 2023 Dec 26;15(1):37.

39. de Kruijff I, Noppe G, Kieviet N, Choenni V, Lambregtse-van den Berg MP, Begijn DG, Tromp E, Dorst K, van Rossum EF, de Rijke YB, van den Akker EL. LC-MS/MS-based reference intervals for hair cortisol in healthy children. Psychoneuroendocrinology. 2020 Feb 1;112:104539.
40. Beaufrère H, Gardhouse SM, Wood RD, Stark KD. The plasma lipidome of the Quaker parrot (Myiopsitta monachus). Plos one. 2020 Dec 1;15(12):e0240449.
41. Lu Z, Li S, Aa N, Zhang Y, Zhang R, Xu C, Zhang S, Kong X, Wang G, Aa J, Zhang Y. Quantitative analysis of 20 purine and pyrimidine metabolites by HILIC-MS/MS in the serum and hippocampus of depressed mice. Journal of Pharmaceutical and Biomedical Analysis. 2022 Sep 20;219:114886.
42. Macklin A, Khan S, Kislinger T. Recent advances in mass spectrometry based clinical proteomics: applications to cancer research. Clinical proteomics. 2020 Dec;17(1):17.
43. Grocholska P, Kowalska M, Bąchor R. Qualitative and quantitative mass spectrometry in salivary metabolomics and proteomics. Metabolites. 2023 Jan 20;13(2):155.
44. Gangnus T. Reliable mass spectrometric techniques for new insights into the kallikrein-kinin system–modern bioanalytical peptide quantitation of an endogenous cascade.
45. Rakete ST. Development and application of a stability-indicating assay method for meropenem and its open-ring metabolite (Doctoral dissertation, lmu).
46. Liu M, He J, Ruan C, Pan W, Mao P, Sun Z, Wang G, Yang J. Simultaneous measurement of amino acid enantiomers in the serum of late-life depression patients using convenient LC–MS/MS method with Nα-(5-fluoro-2, 4-dinitrophenyl)-l-leucinamide Derivatization. Journal of Pharmaceutical and Biomedical Analysis. 2023 Jun 15;230:115387.
47. Grouzmann E, Centeno C, Eugster PJ. Quantification of vanillylmandelic acid, homovanillic acid and 5-hydroxyindoleacetic acid in urine using a dilute-and-shoot and ultra-high pressure liquid chromatography tandem mass spectrometry method. Clinical Chemistry and Laboratory Medicine (CCLM). 2018 Aug 28;56(9):1533-41.
48. Canbay E, Sezer ED, Uçar SK, Çoker M, Sözmen EY. LC-MS/MS measurement of leukocyte cystine; effect of preanalytic factors. Talanta. 2020 Mar 1;209:120558.
49. Pančík F, Pakanová Z, Květoň F, Baráth P. Diagnostics of lysosomal storage diseases by mass spectrometry: a review. Chemical Papers. 2022 Jul;76(7):3995-4004.
50. Santos PM, del Nogal Sanchez M, Pavón JL, Cordero BM. Non-separative method based on a single quadrupole mass spectrometer for the semi-quantitative determination of amino acids in saliva samples. A preliminary study. Talanta. 2020 Feb 1;208:120381.
51. Sun Z, Huang C, Shi Y, Wang R, Fan J, Yu Y, Zhang Z, Zhu K, Li M, Ni Q, Chen Z. Distinct bile acid profiles in patients with chronic hepatitis b virus infection reveal metabolic interplay between host, virus and gut microbiome. Frontiers in Medicine. 2021 Oct 4;8:708495.
52. Angioni D, Hansson O, Bateman RJ, Rabe C, Toloue M, Braunstein JB, Agus S, Sims JR, Bittner T, Carrillo MC, Fillit H. Can we use blood biomarkers as entry criteria and for monitoring drug treatment effects in clinical trials? A report from the EU/US CTAD task force. The journal of prevention of Alzheimer's disease. 2023 Sep;10(3):418-25.
53. Chen CJ, Lee DY, Yu J, Lin YN, Lin TM. Recent advances in LC-MS-based metabolomics for clinical biomarker discovery. Mass spectrometry reviews. 2023 Nov;42(6):2349-78.
54. Maekawa M, Mano N. Cutting-edge LC–MS/MS applications in clinical mass spectrometry: Focusing on analysis of drugs and metabolites. Biomedical Chromatography. 2022 May;36(5):e5347.
55. D'Ovidio C, Locatelli M, Perrucci M, Ciriolo L, Furton KG, Gazioglu I, Kabir A, Merone GM, de Grazia U, Ali I, Catena AM. LC-MS/MS application in pharmacotoxicological field: Current state and new applications. Molecules. 2023 Feb 24;28(5):2127.
56. Plumb RS, Gethings LA, Rainville PD, Isaac G, Trengove R, King AM, Wilson ID. Advances in high throughput LC/MS based metabolomics: A review. TrAC Trends in

Analytical Chemistry. 2023 Mar 1;160:116954.
57. Gajula SN, Khairnar AS, Jock P, Kumari N, Pratima K, Munjal V, Kalan P, Sonti R. LC-MS/MS: A sensitive and selective analytical technique to detect COVID-19 protein biomarkers in the early disease stage. Expert Review of Proteomics. 2023 Mar 4;20(1-3):5-18.
58. Thomas SN, French D, Jannetto PJ, Rappold BA, Clarke WA. Liquid chromatography–tandem mass spectrometry for clinical diagnostics. Nature Reviews Methods Primers. 2022 Dec 8;2(1):96.
59. Westbye AB, Aas FE, Kelp O, Dahll LK, Thorsby PM. Analysis of free, unbound thyroid hormones by liquid chromatography-tandem mass spectrometry: A mini-review of the medical rationale and analytical methods. Analytical Science Advances. 2023 Aug;4(7-8):244-54.
60. Birse N, Burns DT, Walker MJ, Quaglia M, Elliott CT. Food allergen analysis: A review of current gaps and the potential to fill them by matrix-assisted laser desorption/ionization. Comprehensive Reviews in Food Science and Food Safety. 2023 Sep;22(5):3984-4003.
61. Rappold BA. Review of the use of liquid chromatography-tandem mass spectrometry in clinical laboratories: Part II-Operations. Ann Lab Med. 2022 Sep 1;42(5):531-57.
62. Bian Y, Gao C, Kuster B. On the potential of micro-flow LC-MS/MS in proteomics. Expert Review of Proteomics. 2022 Mar 4;19(3):153-64.
63. Panda SS. Bioanalysis of anticancer agents: Evaluating LC-MS/MS procedures with greenness metrics. TrAC Trends in Analytical Chemistry. 2023 Dec 1;169:117394.
64. Kizhakkeppurath Kumaran A, Sahu A, Singh A, Aynikkattil Ravindran N, Sekhar Chatterjee N, Mathew S, Verma S. Proteoglycans in breast cancer, identification and characterization by LC-MS/MS assisted proteomics approach: A review. PROTEOMICS–Clinical Applications. 2023 Jul;17(4):2200046.
65. Rappold BA. Review of the use of liquid chromatography-tandem mass spectrometry in clinical laboratories: part I-development. Annals of Laboratory Medicine. 2022 Mar 1;42(2):121-40.
66. Rabbani N. AGEomics Biomarkers and Machine Learning—Realizing the Potential of Protein Glycation in Clinical Diagnostics. International Journal of Molecular Sciences. 2022 Apr 21;23(9):4584.
67. Birhanu AG. Mass spectrometry-based proteomics as an emerging tool in clinical laboratories. Clinical proteomics. 2023 Dec;20(1):32.
68. Guo J, Kufer R, Li D, Wohlrab S, Greenwood-Goodwin M, Yang F. Technical advancement and practical considerations of LC-MS/MS-based methods for host cell protein identification and quantitation to support process development. InMAbs 2023 Dec 31 (Vol. 15, No. 1, p. 2213365). Taylor & Francis.
69. Alexandridou A, Volmer DA. Sample preparation techniques for extraction of vitamin D metabolites from non-conventional biological sample matrices prior to LC–MS/MS analysis. Analytical and bioanalytical chemistry. 2022 Jul;414(16):4613-32.
70. Baviskar KP, Jain DV, Pingale SD, Wagh SS, Gangurde SP, Shardul SA, Dahale AR, Jain KS. A review on hyphenated techniques in analytical chemistry. Current Analytical Chemistry. 2022 Nov 1;18(9):956-76.
71. Windarsih A, Rohman A, Riswanto FD, Dachriyanus, Yuliana ND, Bakar NK. The metabolomics approaches based on LC-MS/MS for analysis of non-halal meats in food products: a review. Agriculture. 2022 Jul 8;12(7):984.
72. Gelb MH, Basheeruddin K, Burlina A, Chen HJ, Chien YH, Dizikes G, Dorley C, Giugliani R, Hietala A, Hong X, Kao SM. Liquid chromatography–tandem mass spectrometry in newborn screening laboratories. International Journal of Neonatal Screening. 2022 Nov 28;8(4):62.
73. Murray KJ, Villalta PW, Griffin TJ, Balbo S. Discovery of Modified Metabolites, Secondary Metabolites, and Xenobiotics by Structure-Oriented LC–MS/MS. Chemical

research in toxicology. 2023 Oct 20;36(11):1666-82.
74. de Souza ID, Queiroz ME. Advances in sample preparation and HPLC–MS/MS methods for determining amyloid-β peptide in biological samples: a review. Analytical and Bioanalytical Chemistry. 2023 Jul;415(18):4003-21.
75. Lee H, Kim SI. Review of liquid chromatography-mass spectrometry-based proteomic analyses of body fluids to diagnose infectious diseases. International Journal of Molecular Sciences. 2022 Feb 16;23(4):2187.
76. Han T, Cong H, Yu B, Shen Y. Application of peptide biomarkers in life analysis based on liquid chromatography–mass spectrometry technology. BioFactors. 2022 Jul;48(4):725-43.
77. Rankin-Turner S, Heaney LM. Mass spectrometry in the clinical laboratory. A short journey through the contribution to the scientific literature by CCLM. Clinical Chemistry and Laboratory Medicine (CCLM). 2023 Apr 1;61(5):873-9.
78. Shama A, Soni T, Jawanda IK, Upadhyay G, Sharma A, Prabha V. The latest developments in using proteomic biomarkers from urine and serum for non-invasive disease diagnosis and prognosis. Biomarker Insights. 2023 Jul;18:11772719231190218.
79. Lapizco-Encinas BH, Zhang YV. Microfluidic systems in clinical diagnosis. Electrophoresis. 2023 Jan;44(1-2):217-45.
80. Pančík F, Pakanová Z, Květoň F, Baráth P. Diagnostics of lysosomal storage diseases by mass spectrometry: a review. Chemical Papers. 2022 Jul;76(7):3995-4004.
81. Ferreira HB, Guerra IM, Melo T, Rocha H, Moreira AS, Paiva A, Domingues MR. Dried blood spots in clinical lipidomics: optimization and recent findings. Analytical and Bioanalytical Chemistry. 2022 Oct;414(24):7085-101.
82. Cavalcante JD, de Almeida DE, Moraes MS, Santos SR, Pincinato PM, Riciopo PM, de Oliveira LL, Monteiro WM, Ferreira-Junior RS. Challenges and opportunities in clinical diagnostic routine of envenomation using blood plasma proteomics. Toxins. 2023 Feb 27;15(3):180.
83. Agrawal I, Tripathi P, Biswas S. Mass spectrometry based protein biomarkers and drug target discovery and clinical diagnosis in Age-Related progressing neurodegenerative diseases. Drug Metabolism Reviews. 2022 Jan 2;54(1):22-36.
84. Haga Y, Minegishi Y, Ueda K. Frontiers in mass spectrometry–based clinical proteomics for cancer diagnosis and treatment. Cancer Science. 2023 May;114(5):1783-91.
85. de Oliveira Moreira OB, de Souza JC, Marcos J, Candido B, do Nascimento MP, Penna EA, Chellini PR, de Oliveira MA. Capillary electrophoresis applied to human urine analysis for clinical diagnosis: new trends and perspectives. Brazilian Journal of Analytical Chemistry. 2023;10(39):17-51.
86. Zittlau K, Nashier P, Cavarischia-Rega C, Macek B, Späť P, Nalpas N. Recent progress in quantitative phosphoproteomics. Expert Review of Proteomics. 2023 Dec 2;20(12):469-82.
87. Skogvold HB, Rootwelt H, Reubsaet L, Elgstøen KB, Wilson SR. Dried blood spot analysis with liquid chromatography and mass spectrometry: Trends in clinical chemistry. Journal of Separation Science. 2023 Aug;46(15):2300210.
88. Goldis R, Kaplan B, Kukuy O, Arad M, Magen H, Shavit-Stein E, Dori A, Livneh A. Diagnostic challenges and solutions in systemic amyloidosis. International Journal of Molecular Sciences. 2023 Feb 28;24(5):4655.
89. Song M, Bai H, Zhang P, Zhou X, Ying B. Promising applications of human-derived saliva biomarker testing in clinical diagnostics. International Journal of Oral Science. 2023 Jan 4;15(1):2.
90. Borsò M, Agretti P, Zucchi R, Saba A. Mass spectrometry in the diagnosis of thyroid disease and in the study of thyroid hormone metabolism. Mass Spectrometry Reviews. 2022 May;41(3):443-68.
91. Li Y, Si Y, Ma Y, Yin H. Application and prospect of metabolomics in the early diagnosis

of osteoporosis: a narrative review. Bioanalysis. 2023 Nov 1;15(22):1369-79.
92. Pais MV, Forlenza OV, Diniz BS. Plasma biomarkers of Alzheimer's disease: a review of available assays, recent developments, and implications for clinical practice. Journal of Alzheimer's Disease Reports. 2023 May 3;7(1):355-80.
93. Kumari A, Kamboj K, ul Islam S. Exploring the Utilization and Application of Mass Spectrophotometry across Various Fields within Clinical Laboratory Science.
94. Rankin-Turner S, Sears P, Heaney LM. Applications of ambient ionization mass spectrometry in 2022: An annual review. Analytical Science Advances. 2023 Jul;4(5-6):133-53.
95. Sun J, Feng X, Lyu C, Zhou S, Liu Z. Effects of different processing methods on the lipid composition of hazelnut oil: A lipidomics analysis. Food Science and Human Wellness. 2022 Mar 1;11(2):427-35.
96. Anwar A, Abruzzo PM, Pasha S, Rajpoot K, Bolotta A, Ghezzo A, Marini M, Posar A, Visconti P, Thornalley PJ, Rabbani N. Advanced glycation endproducts, dityrosine and arginine transporter dysfunction in autism-a source of biomarkers for clinical diagnosis. Molecular Autism. 2018 Dec;9:1-6.